(FIXX) – FDA
-
Homology Medicines (FIXX) Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
-
Homology Medicines Inc. (FIXX) Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to FIXX Stock Lookup